Vir Biotechnology (VIR) Stock Price, News & Analysis

Company Overview

Vir Biotechnology, Inc. is a clinical-stage immunology company headquartered in San Francisco, California. Established in 2016, the company is focused on leveraging cutting-edge immune-driven technologies to prevent and treat serious infectious diseases. Vir’s research platform integrates immunologic insights with proprietary technologies designed to harness the immune system’s natural ability to fight pathogens.

The company’s pipeline centers on monoclonal antibodies and immunomodulators targeting a range of viral threats. Its most advanced program, developed in collaboration with GlaxoSmithKline, delivers a monoclonal antibody for the treatment and prevention of COVID-19. Beyond SARS-CoV-2, Vir is advancing candidates against seasonal influenza, hepatitis B virus (HBV), respiratory syncytial virus (RSV) and HIV. These programs span discovery through late-stage clinical trials, reflecting a broad commitment to addressing both endemic and emerging viral diseases.

Vir collaborates with government agencies, academic centers and global pharmaceutical partners to accelerate research and development. The company’s international presence is bolstered by strategic alliances in North America, Europe and the Asia-Pacific region, enabling the conduct of multinational clinical studies and facilitating potential commercialization pathways across key markets.

Since its founding, Vir Biotechnology has been led by veteran biotech executives with experience in bringing novel therapeutics to market. The organization maintains research and development operations in the United States and Europe, underscoring its dedication to translating scientific innovation into accessible therapies for patients worldwide.

Key Stats

• Today's Range: $5.31 to $5.62
• 50-Day Range: $4.50 to $5.93
• 52-Week Range: $4.32 to $14.45
• Volume: 2.07 million shs
• Average Volume: 1.37 million shs
• Market Capitalization: $747.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.25
• Consensus Rating: Moderate Buy

Vir Biotechnology Stock Analysis - MarketRank™

Vir Biotechnology scored higher than 72% of companies evaluated by MarketBeat, and ranked 297th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Vir Biotechnology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vir Biotechnology are expected to grow in the coming year, from ($3.92) to ($3.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vir Biotechnology is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vir Biotechnology is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vir Biotechnology has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.45% of the float of Vir Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Vir Biotechnology has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vir Biotechnology has recently decreased by 34.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vir Biotechnology does not currently pay a dividend.

Dividend Growth

Vir Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.45% of the float of Vir Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Vir Biotechnology has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vir Biotechnology has recently decreased by 34.12%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.61

News Sentiment

Vir Biotechnology has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $185,150.00 in company stock.

Percentage Held by Insiders

16.00% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VIR Stock Analysis - Frequently Asked Questions

How have VIR shares performed this year?

Vir Biotechnology's stock was trading at $7.34 at the beginning of 2025. Since then, VIR stock has decreased by 26.3% and is now trading at $5.41.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) released its earnings results on Wednesday, May, 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.05. The business's revenue for the quarter was down 94.6% on a year-over-year basis.
Read the conference call transcript.

When did Vir Biotechnology IPO?

Vir Biotechnology (VIR) raised $149 million in an IPO on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

Who are Vir Biotechnology's major shareholders?

Top institutional shareholders of Vir Biotechnology include State of Alaska Department of Revenue (0.04%), Diversified Trust Co (0.02%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Howard Horn, Ann M Hanly, Steven J Rice, Mark Eisner, Sung Lee, Verneuil Vanina De, Brent Sabatini, Janet Napolitano, Saira Ramasastry and Charles Elliott Sigal.
View institutional ownership trends.

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vir Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIR
• CIK: 1706431
• Web: www.vir.bio
• Phone: 415-906-4324
• Fax: N/A
• Employees: 580
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vir Biotechnology: $30.25
• High Price Target: $110.00
• Low Price Target: $12.00
• Potential Upside/Downside: +459.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$521.96 million
• Net Margins: -2,769.04%
• Pretax Margin: -2,775.77%
• Return on Equity: -47.46%
• Return on Assets: -39.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.79
• Quick Ratio: 6.79

Sales & Book Value

• Annual Sales: $74.21 million
• Price / Sales: 10.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.35 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 138,240,000
• Free Float: 116,120,000
• Market Cap: $747.88 million
• Optionable: Optionable
• Beta: 1.22